logo
How to watch two meteor showers peak together in late July

How to watch two meteor showers peak together in late July

WASHINGTON (AP) — It's almost time for summer's meteor shower duet.
The Southern Delta Aquariid and the Alpha Capricornid meteor showers peak at the same time — in the early morning of July 30.
Without too much interference from moonlight — the waxing moon will be only about a quarter full — the meteors should appear bright and clear in regions away from city lights.
With each shower expected to produce up to a dozen visible meteors per hour under dark skies, the doubleheader means the total number of meteors 'do add up,' said Thaddeus LaCoursiere, planetarium program coordinator at the Bell Museum in St. Paul, Minnesota.
'Look for flashes of light in the night sky,' he said, adding that both are 'very nice classic meteor showers.'
The Alpha Capricornids — produced by slower-moving meteors — may have tails that linger slightly longer in the sky, said Nick Moskovitz of the Lowell Observatory in Flagstaff, Arizona.
Viewing of each shower lasts through August 12.
What is a meteor shower?
As the Earth orbits the sun, several times a year it passes through debris left by passing comets and sometimes asteroids.
The source of the Delta Aquariids is debris from comet 96P/Machholz. The Alpha Capricornids stem from the comet 169P/NEAT.
When these fast-moving space rocks enter Earth's atmosphere, the debris encounters new resistance from the air and becomes very hot, eventually burning up.
Sometimes the surrounding air glows briefly, leaving behind a fiery tail — the end of a 'shooting star.'
You don't need special equipment to see the various meteor showers that flash across annually, just a spot away from city lights.
How to view a meteor shower
The best time to watch a meteor shower is in the early predawn hours when the moon is low in the sky.
Competing sources of light — such as a bright moon or artificial glow — are the main obstacles to a clear view of meteors. Cloudless nights when the moon wanes smallest are optimal viewing opportunities.
And keep looking up, not down. Your eyes will be better adapted to spot shooting stars if you aren't checking your phone.
When is the next meteor shower?
The next major meteor shower, the Perseids, peaks in mid August.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress

Yahoo

time35 minutes ago

  • Yahoo

Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the stocks under $10 to buy now. On July 17, Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study of tegoprubart will be presented at the World Transplant Congress/WTC. The WTC will take place in San Francisco from August 2-6 this year. The oral presentation, titled 'Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,' will feature updated results from ~30 kidney transplant recipients. In addition to the oral presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?' A scientist in a laboratory holding a vial of medication developed by the biotechnology company. Furthermore, new preclinical data on tegoprubart's use for preventing rejection in non-human primates undergoing liver transplantation will be presented in a poster session. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand/CD40L pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis/ALS. While we acknowledge the potential of ELDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients
Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients

Yahoo

timean hour ago

  • Yahoo

Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients

Astria Therapeutics Inc. (NASDAQ:ATXS) is one of the stocks under $10 to buy now. Earlier on June 13, Astria Therapeutics announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart (STAR-0215) in hereditary angioedema/HAE patients. These findings were presented at the European Academy of Allergy and Clinical Immunology/EAACI Annual Congress. The trial showed an overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction. These results support the potential for every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. These initial results from ALPHA-SOLAR are consistent with the 'best-in-class' profile observed in the earlier ALPHA-STAR Phase 1b/2 trial. A closeup of pills in a pharmacy, representing the high quality medications of the company. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR. Patients from ALPHA-STAR Cohorts 1 and 2 joined Arm A, while Cohort 3 patients joined Arm B. Astria Therapeutics Inc. (NASDAQ:ATXS) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the US. While we acknowledge the potential of ATXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data

NASA, Space-X scrub crew-11 launch due to weather
NASA, Space-X scrub crew-11 launch due to weather

Yahoo

time3 hours ago

  • Yahoo

NASA, Space-X scrub crew-11 launch due to weather

NASA and SpaceX canceled today's planned launch of the Crew-11 mission to the International Space Station due to cloud cover at the Kennedy Space Center launch site. They are now targeting 11:43 a.m. EDT on Friday, August 1, for liftoff of the SpaceX Falcon 9 rocket and Dragon spacecraft from Launch Complex 39A. The forecast currently shows a 75% chance of favorable weather at the launch site, though conditions along the Crew Dragon Endeavour flight path remain under review. NASA astronauts Zena Cardman and Mike Fincke, JAXA astronaut Kimiya Yui, and Roscosmos cosmonaut Oleg Platonov safely exited the spacecraft after the scrub. They returned to crew quarters to await their next launch attempt. Docking with the International Space Station is now targeted for approximately 3 a.m. EDT on Saturday, August 2. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store